Macquarie Group’s Karyopharm Therapeutics KPTI Stock Holding History

Macquarie Group’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-33,333	Closed	-$338K	–	1759
2024 Q4	$338K	Hold	33,333	–	–	﹤0.01%	1474
2024 Q3	$415K	Sell	33,333 -379	-1%	-$4.71K	﹤0.01%	1495
2024 Q2	$439K	Buy	33,712 +379	+1%	+$6.28K	﹤0.01%	1480
2024 Q1	$755K	Buy	33,333 +8,000	+32%	+$140K	﹤0.01%	1402
2023 Q4	$329K	Hold	25,333	–	–	﹤0.01%	1512
2023 Q3	$509K	Hold	25,333	–	–	﹤0.01%	1439
2023 Q2	$680K	Hold	25,333	–	–	﹤0.01%	1420
2023 Q1	$1.48M	Hold	25,333	–	–	﹤0.01%	1258
2022 Q4	$1.29M	Sell	25,333 -98	-0.4%	-$6.79K	﹤0.01%	1350
2022 Q3	$2.09M	Sell	25,431 -38	-0.1%	-$2.84K	﹤0.01%	1211
2022 Q2	$1.72M	Hold	25,469	–	–	﹤0.01%	1346
2022 Q1	$2.82K	Hold	25,469	–	–	﹤0.01%	1274
2021 Q4	$2.46M	Hold	25,469	–	–	﹤0.01%	1315
2021 Q3	$2.22M	Hold	25,469	–	–	﹤0.01%	1354
2021 Q2	$3.94M	Buy	25,469 +65	+0.3%	+$9.43K	﹤0.01%	1199
2021 Q1	$4.01M	Sell	25,404 -18	-0.1%	-$3.79K	0.01%	971
2020 Q4	$5.9M	Hold	25,422	–	–	0.01%	843
2020 Q3	$5.57M	Hold	25,422	–	–	0.01%	801
2020 Q2	$7.22M	Buy	25,422 +89	+0.4%	+$26.3K	0.01%	702
2020 Q1	$7.3M	Hold	25,333	–	–	0.02%	634
2019 Q4	$7.29M	Hold	25,333	–	–	0.01%	710
2019 Q3	$3.66M	Hold	25,333	–	–	0.01%	840
2019 Q2	$2.28M	Hold	25,333	–	–	﹤0.01%	983
2019 Q1	$2.22M	Sell	25,333 -20	-0.1%	-$2.22K	﹤0.01%	966
2018 Q4	$3.56M	Buy	25,353 +2,806	+12%	+$473K	0.01%	834
2018 Q3	$5.76M	Sell	22,547 -160	-0.7%	-$44.2K	0.01%	756
2018 Q2	$5.79M	Buy	+22,707	New	+$5.62M	0.01%	746
2018 Q1	–	Sell	-60	Closed	-$9K	–	2271
2017 Q4	$9K	Buy	+60	New	+$9.64K	﹤0.01%	2276

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Macquarie Group's KPTI Position: Q1 2025 in Review

Macquarie Group sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 33,333 shares — an estimated $338K sold.

Macquarie Group first reported a position in KPTI in Q4 2017 and held it in 28 quarters. The position peaked at $7.3M in Q1 2020. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

Macquarie Group reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
Macquarie Group sold 33,333 Karyopharm Therapeutics shares in Q1 2025, an estimated $338K.
Macquarie Group first reported a position in Karyopharm Therapeutics in Q4 2017 and held it in 28 quarters.
Macquarie Group's Karyopharm Therapeutics position peaked at $7.3M in Q1 2020.
49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Macquarie Group's 13F filing for Q1 2025, filed 15 May 2025.